指南与共识哮喘

成人及青少年哮喘与NAEB所致慢性咳嗽管理:CHEST指南与专家小组报告

Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report.
指南 / 共识 · Chest · 2020-01-20

该CHEST指南基于三项系统综述(分别纳入3/1175、53/656、6/134篇文献),评估无创气道炎症检测在哮喘相关咳嗽中的作用及哮喘或NAEB所致咳嗽的最佳治疗。证据显示无创生物标志物对哮喘慢性咳嗽的特异性获益证据较弱,吸入糖皮质激素后白三烯受体拮抗剂是最佳治疗选择。

要点

  • 无创气道炎症生物标志物用于哮喘慢性咳嗽的特异性获益证据较弱。
  • 哮喘或NAEB所致咳嗽的最佳治疗为吸入糖皮质激素,其次为白三烯受体拮抗剂。
  • 指南基于系统综述制定,并指出未来研究的知识空白。

核心结论

  • 无创气道炎症检测在哮喘所致慢性咳嗽中的特异性获益证据较弱。
  • 哮喘或NAEB所致咳嗽的最佳治疗为吸入糖皮质激素,其后为白三烯受体拮抗剂。

研究设计与样本

  • 三项系统综述纳入随机对照试验和观察性试验,对象为12岁以上慢性咳嗽由哮喘或NAEB引起的成人及青少年。
  • 文献检索MEDLINE、CENTRAL和SCOPUS,评估相关性与质量。
  • 采用CHEST指南方法制定推荐并进行投票。

主要发现

  • 三项系统综述分别从1175、656、134篇文献中纳入3、53、6篇合格研究。
  • 与一般哮喘治疗指南及部分指南将气道炎症生物标志物用于指导重症治疗不同,本指南认为非侵入性生物标志物在哮喘慢性咳嗽患者中的特异性获益证据较弱。

关键数值与推荐

  • 哮喘或NAEB所致咳嗽的最佳治疗选择为吸入糖皮质激素,其次为白三烯受体拮抗剂。

临床怎么用

  • 对哮喘或NAEB所致慢性咳嗽,首选吸入糖皮质激素治疗,其次可考虑白三烯受体拮抗剂。
  • 不推荐常规使用无创气道炎症生物标志物来指导哮喘慢性咳嗽的治疗决策。

局限性

  • 证据基础有限,三项系统综述纳入的合格研究数量较少(分别为3、53、6篇)。
  • 指南指出知识空白和未来研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma and non-asthmatic eosinophilic bronchitis (NAEB) are among the commonest causes of chronic cough in adults. We sought to determine the role of non-invasive measurements of airway inflammation, including induced sputum and fractional exhaled nitric oxide, in the evaluation of cough associated with asthma, and what the best treatment is for cough due to asthma or NAEB. METHODS: We undertook three systematic reviews of randomized controlled trials and observational trials of adults and adolescents > 12 years of age with a chronic cough due to asthma or NAEB. Eligible studies were identified in MEDLINE, CENTRAL, and SCOPUS and assessed for relevance and quality. Guidelines were developed and voted upon using CHEST guideline methodology. RESULTS: Of the citations reviewed, 3/1,175, 53/656, and 6/134 were identified as being eligible for inclusion in the three systematic reviews, respectively. In contrast to established guidelines for asthma therapies in general and the inclusion in some guidelines for a role of biomarkers of airway inflammation to guide treatment in severe disease, the evidence of specific benefit related to the use of non-invasive biomarkers in patients with chronic cough due to asthma was weak. The best therapeutic option for cough in asthma or NAEB is inhaled corticosteroids followed by leukotriene receptor antagonism. CONCLUSIONS: This guideline offers recommendations on the role of non-invasive measurements of airway inflammation and treatment for cough due to asthma or NAEB based on the available literature, and identifies gaps in knowledge and areas for future research.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Côté A, Russell RJ, Boulet LP, et al. Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report. Chest. 2020. PMID: 31972181. doi:10.1016/j.chest.2019.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。